Sec Form 3 Filing - Clark George C. @ Biohaven Pharmaceutical Holding Co Ltd. - 2021-08-06

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Clark George C. 2. Issuer Name and Ticker or Trading Symbol Biohaven Pharmaceutical Holding Co Ltd. [ BHVN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) VP, Chief Accounting Officer (Last) (First) (Middle) C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET 3. Date of Earliest Transaction (MM/DD/YY) 08/06/2021 (Street) NEW HAVEN, CT06510 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 5,558 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) $ 71.44 ( 2 ) 05/06/2031 Common Shares 10,000 D Employee Stock Option (right to buy) $ 83.38 ( 3 ) 01/06/2031 Common Shares 7,000 D Employee Stock Option (right to buy) $ 53.76 ( 4 ) 12/05/2029 Common Shares 8,250 D Employee Stock Option (right to buy) $ 32.42 ( 5 ) 11/20/2028 Common Shares 6,710 D Employee Stock Option (right to buy) $ 30.32 ( 6 ) 03/11/2028 Common Shares 1,250 D Restricted Share Unit Award ( 7 ) ( 8 ) ( 9 ) Common Shares 20,000 D Restricted Share Unit Award ( 7 ) ( 10 ) ( 9 ) Common Shares 2,625 D Restricted Share Unit Award ( 7 ) ( 11 ) ( 9 ) Common Shares 2,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Clark George C. C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN, CT06510 VP, Chief Accounting Officer Signatures /s/ George C. Clark 08/13/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This balance includes 700 shares and 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2020 and May 31, 2021, respectively, and 200 shares held in an individual retirement account. ( 10 )The reporting person was granted 3,500 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. ( 11 )The reporting person was granted 4,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date. ( 2 )The shares underlying this option became exercisable as to 2,500 of these shares on May 7, 2021, with the remainder vesting in 3 equal installments on May 7, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date. ( 3 )The shares underlying this option became exercisable as to 1,750 of these shares on January 6, 2021, with the remainder vesting in 3 equal installments on January 6, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date. ( 4 )The shares underlying this option became exercisable as to 3,750 of these shares on and prior to December 5, 2020, with the remainder vesting in 2 equal installments on December 5, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date. ( 5 )The shares underlying this option became exercisable as to 960 of these shares on and prior to November 20, 2020, with the remainder vesting in 2 equal installments on November 20, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date. ( 6 )The shares underlying this option will vest on March 12, 2022, subject to the reporting person's continuing service as of each applicable vesting date. ( 7 )Each restricted share unit represents the contingent right to receive one common share of the Issuer. ( 8 )The reporting person was granted 20,000 restricted share units on May 7, 2021, vesting in four equal installments on May 7, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. ( 9 )Not applicable.

Remarks: Exhibit List:Exhibit 24: Power of attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.